Newsroom

BigHat at WuXi Healthcare Forum 2021

Read more

BigHat Biosciences Chief Business Officer, Liz Schwarzbach, hosted a Roundtable Discussion today during the WuXi Healthcare Forum 2021 discussing the key opportunities to apply AI/ML-enabled antibody design. The group dove into what these key unmet needs are across the therapeutic landscape and what is needed to demonstrate proof of concept for each application.

Posted:

3/16/2021

Read Time:

mins

Words by:

BigHat Biosciences Enters into Strategic Collaboration to Leverage Machine Learning in Antibody Discovery & Design

BigHat’s CIO on Software Engineering Daily podcast

AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies

BigHat on Genetic Engineering & Biotechnology News

BigHat’s CSO on Biocom CA’s Lifelines Podcast

BigHat’s CSO presents at Antibody Engineering and Therapeutics Conference Europe 2023

BigHat Appoints John Corbin, PhD as Chief Development Officer

BigHat Year in Review 2022

BigHat Biosciences Announces Research Collaboration with Merck

BigHat Biosciences validates best-in-class security posture with spotless SOC2 audit

BigHat Biosciences Raises $75 Million in Series B Funding to Design Safer, More Effective Antibodies

BigHat raises $75M Series B

BigHat’s CSO and VP Engineering speaking at AWS Summit San Francisco

BigHat Biosciences Appoints Rob Chess, Serial Entrepreneur, to its Board of Directors

BigHat Biosciences Completes Its Acquisition of Frugi Biotechnology

Luminaries Rob Chess, Mark Pegram and Michael Jewett join BigHat’s Advisory Board

BigHat in Pharma’s Almanac Q1 2022 Issue

BigHat’s CEO and CSO on BIOS Builders podcast

BigHat’s CSO presents at Antibody Engineering and Therapeutics Conference

BigHat Biosciences Completes First Stage of Research Collaboration with Amgen

BigHat Holiday Memo 2021

BigHat’s New Facility

BigHat Wins “2021 Therapeutics Innovation of the Year” from BioTech Breakthrough

BigHat selected as the winner at the UCSF Health Awards

BigHat’s CSO on Moneyball Medicine podcast

BigHat featured on Pinpoint Case Study

BigHat’s VP of Engineering featured on AWS Healthcare and Life Sciences CTO Fellowship

BigHat named to Business Insider’s top 24 Biotech startups by leading VCs

Healthcare finance expert Amol Pawar joins BigHat Advisory team

BigHat publishes research on active learning applied to proteins at the 2021 ICML Workshop on Computational Biology

BigHat CSO and Co-Founder Peyton Greenside recognized as one of Silicon Valley Business Journal’s Women Of Influence for 2021

BigHat Featured on AWS DevOps Blog

BigHat presents at AI for Drug Discovery 2021 conference

BigHat founders discuss AI for Biologics with a16z on Clubhouse

BigHat at WuXi Healthcare Forum 2021

BigHat CSO on the future of machine learning and computational biology at Stanford Computer Science AI Salon

BigHat Biosciences Raises $19 Million in Series A Funding to Advance Antibody Design and Development for Safer, More Effective Treatments

BigHat raises $19M Series A

Antibody developer Steve Doberstein joins BigHat advisory team

Peyton Greenside, BigHat CSO, speaks about machine-guided biological design

BigHat Biosciences earns Phase I award from NIST to show power of AI-driven platform

BigHat awarded 2020 Golden Ticket from Amgen and MBC Biolabs

BigHat founder discusses COVID-19's impact on early-stage startups

BigHat founder presents active learning innovations at ICML 2020

BigHat founder speaks at the annual European Society for Human Genetics (ESHG) 2020 meeting

BigHat founder talks leading interdisciplinary teams with Stanford Accel Scholars

BigHat founder at the Cell Free Systems conference

BigHat founder moderates Deep Life salon

BigHat founder speaks at Open Data Science conference

BigHat closes oversubscribed seed round